What is the recommended prophylactic dose of rivaroxaban (Xarelto) for venous thromboembolism prevention, including duration after total hip or knee replacement and renal function considerations?

Xarelto Prophylactic Dosing

For VTE prophylaxis after total hip or knee replacement surgery, rivaroxaban (Xarelto) should be dosed at 10 mg once daily, started 6-10 hours after surgery, continued for 10-14 days after total knee arthroplasty and up to 35 days after total hip arthroplasty. 1

Dosing by Indication

Orthopedic Surgery (Hip or Knee Replacement)

• Standard dose: 10 mg once daily 1, 2
• Timing of first dose: 6-10 hours after surgery 1, 3
• Duration:
  • Total knee arthroplasty (TKA): 10-14 days 1, 2
  • Total hip arthroplasty (THA): 28-35 days 1, 2

This dosing was established in the RECORD trials, which demonstrated that rivaroxaban 10 mg once daily was noninferior to enoxaparin for VTE prophylaxis after major orthopedic surgery 1. Extended duration rivaroxaban (31-39 days) after hip arthroplasty proved more effective than short-course enoxaparin (10-14 days) without increased bleeding 1.

Renal Function Considerations

Rivaroxaban should be avoided in patients with severe renal impairment (CrCl <30 mL/min) for the VTE prophylaxis indication 4, 3. The drug undergoes 66% renal excretion, and severe renal dysfunction significantly increases drug exposure 4.

For patients with moderate renal impairment (CrCl 30-50 mL/min):

• Use with caution 4
• The standard 10 mg once daily dose can still be used for orthopedic prophylaxis 2
• Recent evidence suggests the approved dosages may be safe even with CrCl 15-30 mL/min, though this remains off-label 5

Important Clinical Caveats

Contraindications for Prophylactic Use

• Severe renal insufficiency (CrCl <30 mL/min) 4, 3
• Hepatic disease associated with coagulopathy 3
• Concomitant systemic treatment with strong CYP3A4 and P-glycoprotein inhibitors (azole-antimycotics, HIV protease inhibitors) 3
• Carbamazepine and other strong CYP3A4 inducers significantly decrease rivaroxaban levels and should be avoided 6

Not Recommended Populations

Rivaroxaban is NOT recommended for VTE prophylaxis in acutely ill general medical patients 1. The MAGELLAN trial showed that while rivaroxaban was noninferior to enoxaparin, it was associated with higher bleeding risk in this population 1.

Bleeding Risk

The prophylactic dose of rivaroxaban (10 mg daily) has a favorable bleeding profile. In pooled analysis of orthopedic surgery trials, major bleeding occurred in 0.3% of rivaroxaban patients versus 0.2% with enoxaparin (not statistically significant, P=0.23) 7. However, some studies noted increased hidden blood loss and wound complications compared to aspirin or LMWH 8.

Perioperative Management

When rivaroxaban must be stopped before surgery:

• Discontinue 3 days before high-bleeding-risk procedures when CrCl >30 mL/min 2
• No bridging therapy needed for most patients 2
• Resume at least 6 hours postoperatively for prophylactic dosing, or 24-72 hours for therapeutic dosing depending on bleeding risk 2

Monitoring

No routine coagulation monitoring is required 3. Standard PT/INR and aPTT are not reliable for measuring rivaroxaban effect due to variable reagent sensitivity 3.